Status:
NOT_YET_RECRUITING
Long-term Follow-up Study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj
Lead Sponsor:
Kang Stem Biotech Co., Ltd.
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
19+ years
Brief Summary
A multi-center, open, long-term follow-up study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD inj. for Moderate to Severe Chronic Atopic Dermatitis: 5-year Results f...
Eligibility Criteria
Inclusion
- Subject who enrolled K0104 Clinical Trial(parent study).
- Subjects who understand and voluntarily sign an informed consent form
Exclusion
- Subjects who are expected to be unable to perform at least one follow-up during this study (K0104-E)
- Subjects who has received/administered clinical trial drugs or medical devices by participating in other clinical trials until the first visit of this trial (K0104-E) after the completion of K0104 clinical trial
- Subjects who are judged to be unsuitable for other researchers to participate in the research
Key Trial Info
Start Date :
March 27 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2030
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT04730024
Start Date
March 27 2022
End Date
June 30 2030
Last Update
January 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dongguk University Medical Center
Ilsan, South Korea